Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now

Affiliations

¹ Department of Surgery, Urology Division, Faculty of Medicine, Laval University, Quebec City, Canada; Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Canada. Electronic address: frederic.pouliot@crchudequebec.ulaval.ca.
² Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.

Editorial

Frédéric Pouliot et al. Eur Urol. 2023 Oct.

. 2023 Oct;84(4):371-372.

doi: 10.1016/j.eururo.2023.07.007. Epub 2023 Jul 28.

¹ Department of Surgery, Urology Division, Faculty of Medicine, Laval University, Quebec City, Canada; Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Canada. Electronic address: frederic.pouliot@crchudequebec.ulaval.ca.
² Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.

No abstract available

Comment on

Diagnostic Performance and Safety of Positron Emission Tomography with ¹⁸F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702